Explore All Access
Check if your research matches the topics covered in Lung Cancer: Targets and Therapy?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Lung Cancer: Targets and Therapy : Impact Factor & More
eISSN: 1179-2728pISSN: 1179-2728
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Lung Cancer: Targets and Therapy Key Metrics
CiteScore 
6.5
SNIP
1.15
Time to Accept
3
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months38%
4 to 6 months50%
7 to 9 months13%
Above 9 months0%
Did you find this useful?
Lung Cancer: Targets and Therapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Lung Cancer: Targets and Therapy
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.
- 1 Apr 2025
- Lung Cancer (Auckland, N.Z.)
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer.
- 1 Apr 2025
- Lung Cancer (Auckland, N.Z.)
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC.
- 1 Feb 2025
- Lung Cancer (Auckland, N.Z.)
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival.
- 1 Jan 2025
- Lung Cancer (Auckland, N.Z.)
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).
- 1 Jan 2025
- Lung Cancer (Auckland, N.Z.)
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
- 1 Dec 2024
- Lung Cancer: Targets and Therapy
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.
- 1 Apr 2025
- Lung Cancer (Auckland, N.Z.)
Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer.
- 1 Apr 2025
- Lung Cancer (Auckland, N.Z.)
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC.
- 1 Feb 2025
- Lung Cancer (Auckland, N.Z.)
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival.
- 1 Jan 2025
- Lung Cancer (Auckland, N.Z.)
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).
- 1 Jan 2025
- Lung Cancer (Auckland, N.Z.)
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
- 1 Dec 2024
- Lung Cancer: Targets and Therapy
